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ABSTRACT 
Objective: The aim of the present study was to develop and evaluate the monolithic osmotic tablet (MOT) composed of the solid dispersion of 
ketoprofen (KETO), a poorly water-soluble drug. Solid dispersion technique is generally used for immediate release, as this maximizes the amount 
of drug absorbed. Sustained release may be obtained by combining solid dispersion technique with MOT so as to increase the therapy efficacy and 
patient compliance. 
Methods: Solid dispersion of KETO was prepared by using solvent melt method with polyethylene glycol (PEG) 6000, a hydrophilic carrier. The 
ratio of KETO to PEG 6000 were 1:1, 1:3 and 1:5 (%w/w). These solid dispersions were characterized by differential scanning calorimetry (DSC), 
Thermogravimetric analysis (TGA) and powder X-ray diffraction (PXRD) to ascertain whether there were any physicochemical interactions between 
drug and carrier.  
The tablet core was prepared by using Polyox N80 (a suspending agent), sodium chloride (an osmotic agent), a solid dispersion consisting of PEG 
6000 and KETO followed by a coating of cellulose acetate to make the monolithic osmotic tablet. 
Results: The results of DSC and PXRD indicated that the drug was in the amorphous state in solid dispersion when PEG 6000 was used as a carrier. 
The dissolution rate of the solid dispersion was much faster than those for the corresponding physical mixture and pure drug. The optimized MOT 
formulations were able to deliver KETO at the constant zero order release, above 95% in vitro, independent to environmental media and stirring 
rate. The release rate of KETO in the MOT is controlled by osmotic pressure, suspending agent and drug solubility in solid dispersion.  
Conclusion: The monolithic osmotic tablet containing solid dispersion has great potential in the controlled delivery of ketoprofen, a water-insoluble drug.  
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The bioavailability of poorly water-soluble drugs is well known to be 
limited and profoundly affected by the rate of absorption in the 
gastrointestinal tract (GIT). As the low solubility of drugs is one of 
the most important factors affecting the drug release process, many 
methods have been proposed to enhance the drug solubility. Among 
the several strategies available for improving drug bioavailability, 
solid dispersions (SDs) have been used extensively [1-6]. The SD 
technique produces a significant increase in surface area and surface 
wettability as well as solid state modification from crystalline to 
amorphous form. Hence, SD is widely used to increase the solubility, 
dissolution rate, and bioavailability of water-insoluble drugs [7-8].  
The monolithic osmotic tablet (MOT) system, which is composed of a 
monolithic tablet coated with cellulose acetate (CA) membrane drilled 
with an orifice on one or both surfaces, utilizing osmotic pressure for 
the delivery of drugs. The osmotic tablets have many advantages, such 
as reducing the risk of adverse reactions and improving patient 
compliance. Drug release from these systems is independent of pH and 
hydrodynamic conditions of the GIT to a large extent, and the release 
characteristics can be adjusted easily by formulation parameters [9-
10]. The MOT system is simple to be prepared as exempting from push 
layer and simplifying in the orifice drilling compared with the push–
pull osmotic tablet and used in the drug controlled delivery field, 
especially suitable for water-insoluble drugs [11].  
However, solid dispersion is generally for immediate release, as this 
maximizes the amount of drug absorbed. Sustained release may be 
obtained by combining solid dispersion technique with MOT so as to 
increase the therapy efficacy and patient compliance. It is a new concept 
to combine the solid dispersion technique and osmotic pump technique 
for water-insoluble drugs in order to obtain much higher solubility and 
controlled release of water-insoluble drugs at the same time.  
In the present study aimed to develop a MOT containing solid-
dispersions of Ketoprofen (KETO). Ketoprofen [(RS)-2-(3-
benzoylphenyl) propionic acid is an important nonsteroidal anti-
inflammatory drug (NSAID), effectively used in the treatment of 
rheumatoid arthritis, osteoarthritis [12] and musculoskeletal 
disorders [13]. 
 
Because of its short elimination half-life (4.2 h) which 
requires multiple dosing to achieve and maintain therapeutic 
concentration and poor aqueous solubility (0.13 mg/ml at 25 °C) [14], 
hazards of adverse gastrointestinal (GI) reactions like gastric irritation, 
peptic ulceration and bleeding can occur. Development of oral 
sustained release formulations of this drug is highly desirable in order 
to achieve improved therapeutic efficacy and patient compliance [15]. 
 
Fig. 1: Chemical structure of Ketoprofen 
 
The characteristic of the SDs of KETO was studied by in vitro 
dissolution, DSE, TGA and X-ray diffraction. The influences of 
formulation variables were also investigated. The optimized MOT of 
KETO solid dispersion was evaluated for effects of solid dispersion, 
the ratio of osmotic agent to suspending agent, the amount of 
plasticizer in the coating, membrane weight gain, and orifice size. 
MATERIALS AND METHODS 
Materials 
KETO with a purity of 99.7% was taken from M/s Ranbaxy 
Laboratories Ltd. (Gurgaon, India), PEG 6000, sodium chloride 
(NaCl); polyethylene glycol 1500 (PEG 1500), and cellulose acetate 
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(CA) with 39.7 wt % acetyl content (Mw, 50,000 g/mol) were 
procured from Thermo Fisher scientific (Mumbai, India); 
polyethylene oxides (polyox WSR N-80; Mw appro. 200,000) was 
procured from Colorcon (Goa, India). All other chemicals were of 
Analytical reagent grade and used without further purification. 
Methodology 
Preparation of solid dispersion (SD) 
The solid dispersions of KETO with PEG 6000 were prepared by the 
solvent melt method [16] in drug: carrier at 1:1, 1:3 and 1:5 (%w/w) 
ratio. A sufficient amount of ethanol was used to dissolve KETO. The 
melted PEG 6000 was added into the KETO solution under stirring at 
70 °C to maintain better dispersion of the drug and to evaporate the 
small amount of ethanol that was used as the solvent. The melt mass 
was solidified immediately in a freezing mixture of ice and sodium 
chloride under constant stirring. The mass was pulverized and sifted 
through 100 ASTM sieve and stored in a desiccator over fused 
calcium chloride for 24 h. 
Preparation of physical mixtures (PM)  
Physical mixtures (PM) of KETO and PEG 6000 were prepared at 1:1, 
1:3, and 1:5 (%w/w) ratio by shifting the individual powders 
through a 60 ASTM sieve and mixing together by trituration in a 
mortar with a pestle. The mixture was stored in a desiccator 
containing calcium chloride for further use.  
Characterization of physical mixtures (PM) and solid dispersion 
(SD) 
Differential scanning calorimetry (DSC) 
DSC thermograms were recorded on a differential scanning 
calorimeter (Perkin Elmer DSC Pyris 1). Samples were heated at a 
scanning rate of 10 °C/min. 
Thermogravimetric analysis (TGA) 
TGA (Perkin-Elmer TGA-7 Pyris 1) was performed to evaluate the 
thermostability of the KETO for the suitability of SD preparation by 
solvent melt method. 
Powder X-ray diffraction (PXRD) 
The scanning PXRD patterns of pure drug (KETO), carrier (PEG 
6000) and their SDs with corresponding PMs were obtained on an X-
ray diffractometer (X’PERT-PRO) under the following conditions:  
Ni-filtered Cu-Kα radiation; 45 kV voltage: 40 mA current, scan 
speed 2 °/min in terms of 2θ angle.  
These PXRD were used to characterize the physical state of the drug 
in the SDs and PMs. Samples were scanned over a range of 2θ values 
from 5 to 50 °, at a scan rate of 2.0 °/min. 
Preparation of MOT 
The powder sample of KETO solid dispersion was mixed with other 
excipients (all 40-ASTM sieved) to prepare granules by using water 
and wet granulation method. The resulting wet granules were dried 
at 60 °C for 1 h and after that, these dried granules were passed 
through 30 ASTM sieve. The final granules were blended with 
magnesium stearate and Talc (sieved through # 60 ASTM) for 10 
min. The lubricated powder was compressed into tablets having an 
average weight of 1000 mg using a 16 station rotary tablet 
compression machine (Cadmach Ahmedabad, India) fitted with 12 
mm round standard concave punches. The core formulations are 
listed in table 1. 
The core tablets were coated using a coating pan (Ganson Thane, 
Mumbai) with a diameter of 25 inches. Acetone containing cellulose 
acetate (CA; 30 g/l, w/v) and a certain amount of plasticizer (PEG 
1500) was used as the coating solution (table 2). Core tablets were 
placed in the coating pan along with 200 g dummy tablets (tablets 
made using 9-mm round deep concave punches, containing 
microcrystalline cellulose PH 102, lactose DCL 11, and magnesium 
stearate) with a pan rotating rate of 10 rpm. The outlet air 
temperature was maintained between 20 °C to 25 °C. The coating 
solution was sprayed at the rate of 3 to 5 ml/minute until desired 
weight gain was obtained on the active tablets. All the tablets were 
dried for 2 h at 50 °C and then an orifice was drilled manually by 
0.25 mm drill on one side of the tablets. 
 
Table 1: Quantitative composition of core tablets 
S. No. Ingredients Formulation code ingredients (mg/tablet) 
T1 T2 T3 T4 T5 
1 SD1  200 - - - - 
2 SD2  - 400 - - - 
3 SD3  - - 600 600 600 
4 Polyox WSR N80 140 140 140 185 95 
5 Sodium chloride 140 140 140 95 185 
6 Microcrystalline cellulose PH102 q. s. q. s. q. s. q. s. q. s. 
7 Magnesium stearate 10 10 10 10 10 
8 Talc 10 10 10 10 10 
Total weight (mg) 1000 1000 1000 1000 1000 
 
Table 2: Coating compositions 
Ingredients Code/coating compositions (gm) 
C1 C2 C3 C4 C5 
Cellulose acetate 398-10  5.0 5.0 5.0 5.0 5.0 
PEG 1500 0.1 0.2 0.3 0.2 0.2 
Purified water@ 10 10% w/w 10 10 10 10 
Acetone@ 100 q. s. 100 100 100 100 
Weight gain (% w/w) 3.0 3.0 3.0 4.0 5.0 
@
 
Evaporates during processing and is not a part of the final product. 
In vitro dissolution studies  
In vitro dissolution tests of the pure drug, powdered SDs, PMs and 
monolithic osmotic tablet (MOT) (equivalent to 100 mg KETO) were 
performed using the dissolution apparatus (Electrolab, Mumbai, 
India) type II paddle method at 37±0.5 °C for 60 min for pure drug, 
powdered SDs, PMs and for MOT 12 h, with a stirring rate of 100 
rpm, in 900 ml of a dissolution medium phosphate buffer pH 6.8. 
Aliquots of dissolution samples were collected at 0.5, 1, 2, 4, 6, 8, 10 
and 12 h time interval, with the replacement of an equal volume of 
temperature-equilibrated dissolution medium. The samples were 
filtered through a 0.45μm membrane filter, and the concentration of 
the drug was determined by UV spectrophotometry at 260 nm.  
All samples were analyzed in triplicate, and release curves were 
plotted using calculated mean values of % cumulative drug release. 
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In order to estimate the effects of pH value of in vitro release 
mediums and paddle rotation rates on drug release behaviour, 
release tests were conducted with pH 1.2 buffer and pH 6.8 
phosphate buffer at 100 rpm, and at a stirring rate of 75, 100 and 
125 rpm with pH 6.8 phosphate buffer, respectively. All experiments 
were also carried out in triplicate.  
RESULTS AND DISCUSSION 
Characterization of solid dispersions 
To increase the oral absorption of poorly water-soluble drugs, it is 
very important to improve the drug solubility and dissolution rate in 
the GIT. Fig. 2 shows the dissolution profile of KETO in a physical 
mixture and solid dispersion in comparison with pure KETO powder.  
DSC curve of KETO, PEG 6000 and SD in 1:5 ratio shows that the 
thermogram of KETO exhibited an endothermic peak at about 99.24 
°C (fig. 3 a) corresponding to its melting point. The endothermic 
peak corresponding to melting peak of KETO disappeared in the case 
of PM and SD with the PEG 6000 (fig. 3 c). The disappearance of drug 
melting in a lesser amount of drug is due to its dissolution in the 
melted carrier. Ketoprofen homogenizes with the carriers in an 
amorphous form. 
The TGA shows, there is no degradation of KETO was observed up to 
160 °C (M. P. of KETO is 99.24 °C) (fig. 4), this confirm that solvent 
melt method is suitable for KETO solid dispersion preparation. 
 
 
Fig. 2: In vitro dissolution profile of ketoprofen, PM (1:5 ratio), 
SD (1:5 ratio) in phosphate buffer pH 6.8 (n=3) 
 
 
Fig. 3: DSC curve: (a) ketoprofen; (b) PEG6000; (c) ketoprofen and PEG 6000 SD (1:5) 
 
Kaushik et al. 




Fig. 4: TGA thermogram of ketoprofen 
 
The dissolution characteristic of KETO physical mixture with PEG 
6000 was similar to pure KET, as KETO was still in the crystal form, 
but far away from the dispersed form in solid dispersion. It was 
reported that PEG 6000 was able to dissolve more drug in 
molecularly dispersed form while hindering precipitation of the 
drug following the dissolution of the carrier [17].  
In order to confirm the differences in crystal form between the 
physical mixture and solid dispersion of KETO, crystal form of the 
physical mixture and of the solid dispersion were investigated by X-
ray diffraction (fig. 5). The X-ray diffraction indicated that KETO 
might be maintained as molecular or amorphous dispersion, which 
resulted in the enhancement of dissolution. But the drug in the 
physical mixture did not show much difference in the dissolution 
profile as it was still in the crystal form [18]. This implied that it was 
the formation of solid dispersion that enhanced the drug dissolution, 
not only the solubilization and wetting effects of the physical 
mixture with PEG 6000. 
 
 
Fig. 5: X-ray diffraction of (a) ketoprofen; (b) ketoprofen and PEG 6000 PM (1:5); (c) Ketoprofen and PEG 6000 SD (1:5) 
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Evaluation of monolithic osmotic tablet 
Effects of solid dispersion 
Tablets with a solid dispersion of different formations were 
prepared and evaluated in vitro release profile. The data in fig. 6 
demonstrated that the release profile varied with the change of 
carrier to drug ratio. The lower release rate was attributed to the drug 
to carrier ratio at 1:1 because the solubility of KETO was lower, which 
was crucial in the release of water insoluble drug from the osmotic 
tablet. The drug may be delivered by the extrusion, either in the form 
of a suspension of solids in water or, primarily, as a solution, 
depending on the dissolution dynamic of the core [19]. Also in drug to 
carrier ratio at 1:3 much bitter release was observed. In the drug 
carrier ratio at 1:5 constant release was observed up to 12 h. 
 
 
Fig. 6: In vitro drug dissolution profile of MOTs containing 
different solid dispersions in phosphate buffer pH 6.8 (n=3) 
 
Effects of ratio of osmotic agent to suspending agent  
The ratio of osmotic agent to suspending agent had some influence on 
the release profile as shown in fig. 7. The more NaCl incorporated into 
the tablet, the more components in the core would be dissolved so that 
the viscosity of the core decreased and thus more drug was released. 
However, a lower amount of Polyox N80, which played the role of 
suspending agent, would affect cumulative release. Lower amounts of 
Polyox N80 led to lower viscosity of the suspension and hardly 
prevented precipitation of KETO. This was consistent with reported 
results that osmotic and suspending agents in MOT had a coordinative 
important effect on the release profile [20]. As a consequence, a 
moderate NaCl/Polyox N80 rate approximate to 1 was selected. 
 
 
Fig. 7: In vitro drug dissolution profile of MOTs containing 
different ratio of osmogen to suspending agent in phosphate 
buffer pH 6.8 (n=3) 
 
Effects of amount of plasticizer 
Besides the formulation of the tablet, the membrane is also a key 
factor affecting the release profile of the monolithic osmotic tablet 
(MOT). As PEG 1500 is a hydrophilic plasticizer, it would be reached 
easily and left behind a wholly porous structure which increases 
membrane permeability and drug release rate [21]. The increase of 
PEG content led to an increase of drug release rate shown in fig. 8. As 
the amount of PEG 1500 increased into the membrane, the more 
void space formed and permeability of the membrane increased. 
Thus, a higher release rate occurred. 
 
 
Fig. 8: In vitro drug dissolution profile of MOTs containing 
different amount of plasticizer in the coating of MOTs in 
phosphate buffer pH 6.8 (n=3) 
 
Effects of membrane weight gain 
To study the effects of membrane thickness on the drug release, 
tablets were coated with different weight gain. Fig. 9 shows that 
drug release decreased with the increased of the weight gain of the 
membrane. As the weight gain increased, the resistance of the 
membrane to water diffusion increased, and the rate of imbibing 
water decreased. As a consequence, the drug release rate was 
reciprocal to the weight gain. It was found that coating formulation 
C2 together with optimal tablet formulation T3 could attain 
approximate zero-order release pattern. 
 
 
Fig. 9: In vitro drug dissolution profile of MOTs containing different 
coating membrane weight gain in phosphate buffer pH 6.8 (n=3) 
 
Effects of orifice size 
It was reported that orifice sizes should be kept in an appropriate 
range so as to maintain zero-order release. Orifice sizes must be 
smaller than the maximum limit, to avoid diffusion delivery through 
the orifice, and larger than the minimum limit, to minimize 
hydrostatic pressure inside the system [22]. The tablet core T3 was 
coated with formulation C2 and was subsequently drilled with a 
circular orifice of the same diameter on each side of the surface. Fig. 
11 shows the effects of orifice size on release profile. 
Orifice sizes between 200 µm to 300 µm could maintain steady 
release and high cumulative release percentage, while an orifice size 
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of 100 µm resulted in lower release rate as drug suspension may 
occlude such a small orifice, therefore leading to a low release rate. 
An orifice diameter of 200 µm to 300 µm contributed to a similar 
release profile as it was within the optimal range. The orifice size 
was measured with stage micrometer and microscope. The MOT 
orifice is shown in fig. 10. 
  
 
Fig. 10: MOT; Upper surface view, MOT; Vertical cross section view 
 
 
Fig. 11: In vitro drug dissolution profile of MOTs containing 
different orifice size in phosphate buffer pH 6.8 (n=3) 
 
Evaluation of the optimized formulation 
To investigate the influence of release media on drug release, in vitro 
releases were tested in pH 1.2 buffers and pH 6.8 phosphate buffer 
at 100 rpm. Optimized formulation exhibits a linear release pattern 
up to 12 h, and no significant difference in release profile could be 
found in different release media (p>0.05). Therefore, it may be 
expected that the drug release from MOT in the GI fluid exhibited a 
media-independent characteristic. The influences of stirring rate on 
drug release profile (at 75, 100, and 125 rpm) were also examined, 
respectively. Increasing agitation rate did not influence the release 
profile significantly (p>0.05). Thus the mobility of the GIT may 
scarcely affect the drug release of the MOT. Drug release was 
independent on release media and agitation rate, and the monolithic 
osmotic tablet was reported to exhibit a comparable in vitro/in vivo 
release profile [21].  
As for the water-insoluble drug, the solubility would be too low to 
form a homogeneous drug suspension and affect drug dissolution. 
Thus, solid dispersion formation was applied so as to enhance the 
solubility and the dissolution rate. NaCl as the osmotic agent played 
an indispensable role because the osmotic mechanism was the main 
energy source to imbibe water and the basis of all osmotic delivery 
systems. In addition, carrier PEG 6000 also has the osmotic effect to 
some extent [23]. Meanwhile, suspending agent polyox N80 was 
applied to increase the viscosity, stabilize the suspension, and 
swelling. In operation, water was imbibed owing to the osmotic 
pressure difference between the inside of the tablet membrane and 
the outside environment, which was contributed by NaCl. Then KET 
in solid dispersion form dissolved, and a viscous KETO suspension 
was created as polyox imbibed water and swelled. The solid 
dispersion facilitated rapid dissolution and higher drug 
concentration within the tablet, and the drug suspension was 
pumped out through the orifices. The drug release was controlled by 
osmotic and suspension mechanisms, while the solid dispersion 
form was utilized to increase drug solubility, dissolution rate, and 
dispersion degree. It was reported that Poiseuille’s law of laminar 







……… Eq. 1 
Where:  
dM/dt = drug release rate, 
C = concentration of drug in tablet suspension, 
r = radius of the orifice,  
η = viscosity of tablet suspension, 
(P1–P2
h = thickness of the membrane.  
) = pressure difference between the inside and outside of the 
membrane 
In this MOT containing KETO in solid dispersion form, C is largely 
dependent on the solubility of KETO in solid dispersion and 
dispersed degree in tablet core. Solid dispersion helped to improve 
drug dissolution rate and maintain a high and constant drug 
concentration in the core. This is because the drug in solid 
dispersion is in supersaturation form. (P1–P2
CONCLUSION 
) represents both 
osmotic pressure and swelling effect, and it was that force driving 
the drug release. The drug release rate is inversely proportional to η 
and. If η value is too high, the release rate will be decreased, as a 
swelling effect could not maintain well-proportioned suspension; if η 
value is too low, the solid drug dispersion may precipitate and be 
unable to maintain C high enough for constant release. In summary, 
drug release from MOT containing solid dispersion can be 
contributed to the osmotic, suspending, and solubility enhancement. 
MOT containing a solid dispersion of KETO were prepared. Solid 
dispersion consisted of PEG 6000 and KETO could enhance the 
solubility, dissolution rate of water-insoluble drug KETO. Drug 
release was investigated in vitro. The optimal MOT was able to 
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deliver KETO at a constant rate of 6.25 mg/hour for up to 12 h in 
phosphate buffer pH 6.8, and cumulative release at 12 h is above 
95%, independent of environment media and stirring rate. The 
release is controlled by osmotic and suspending effect while 
integrating solid dispersion for solubility enhancement. MOT was 
simple to prepare and there is no need to differentiate the orifice 
drill surface. The MOT containing solid dispersion has great 
potential in the controlled delivery of water insoluble drugs. 
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